# Ferdinandos Skoulidis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ferdinandos-skoulidis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,602 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 45 |
| i10-index | 83 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5048517627 |
| ORCID iD | https://orcid.org/0000-0002-4676-4503 |
| Works | 460 |

## Researcher papers

Showing 12 of 14.

- [Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation](https://scholariq.org/papers/sotorasib-for-lung-cancers-with-i-kras-i-p-g12c-mutation/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study](https://scholariq.org/papers/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients/)
- [Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study](https://scholariq.org/papers/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for/)
- [Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy](https://scholariq.org/papers/co-occurring-genomic-alterations-in-non-small-cell-lung-cancer-biology-and/)
- [Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment](https://scholariq.org/papers/stk11-lkb1-deficiency-promotes-neutrophil-recruitment-and-proinflammatory/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition](https://scholariq.org/papers/a-patient-derived-pan-cancer-emt-signature-identifies-global-molecular/)
- [CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade](https://scholariq.org/papers/cd38-mediated-immunosuppression-as-a-mechanism-of-tumor-cell-escape-from-pd-1-pd/)
- [Structure-based classification predicts drug response in EGFR-mutant NSCLC](https://scholariq.org/papers/structure-based-classification-predicts-drug-response-in-egfr-mutant-nsclc/)
- [Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status](https://scholariq.org/papers/diminished-efficacy-of-programmed-death-ligand-1-inhibition-in-stk11-and-keap1/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.